By Fineline Cube Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a Phase II/III clinical study evaluating its investigational pimurutamab (HLX07) in combination with HanSiZhuang (serplulimab) plus chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC) in China.
Clinical Development Program
| Parameter | Detail |
|---|---|
| Study Phase | Phase II/III (seamless design) |
| Indication | First-line advanced squamous NSCLC |
| Combination Regimen | HLX07 + HanSiZhuang (serplulimab) + chemotherapy |
| Patient Population | Treatment-naïve advanced sqNSCLC patients in China |
| Primary Endpoints | Progression-free survival (PFS) and overall survival (OS) |
| Study Status | First patient dosed – active recruitment |
Product Portfolio Overview
HLX07 (Pimurutamab)
- Molecule Type: Recombinant humanized anti-EGFR monoclonal antibody (mAb)
- Target Indication: Advanced solid tumors
- Development Stage: Investigational – not yet approved
- Mechanism: EGFR inhibition to block tumor growth signaling pathways
HanSiZhuang (Serplulimab)
- Molecule Type: Innovative anti-PD-1 monoclonal antibody (mAb)
- Regulatory Status: Already approved for marketing in China
- Approved Indications:
- First-line sqNSCLC (in combination with chemotherapy)
- Extensive-stage small cell lung cancer (ES-SCLC)
- Esophageal squamous cell carcinoma (ESCC)
- Non-squamous NSCLC (nsqNSCLC)
Strategic Rationale & Clinical Innovation
- Dual-Target Approach: Combines EGFR inhibition (HLX07) with PD-1 blockade (HanSiZhuang) plus standard chemotherapy
- Rationale: EGFR expression is common in sqNSCLC; combining targeted therapy with immunotherapy may enhance anti-tumor response
- Competitive Advantage: Leverages Henlius’ already-approved anti-PD-1 backbone with novel anti-EGFR agent
- Market Opportunity: Addresses approximately 40% of NSCLC cases that are squamous subtype
- Unmet Need: Limited targeted therapy options currently available for sqNSCLC compared to non-squamous NSCLC
Market Context & Competitive Landscape
- NSCLC Market Size: $25+ billion global market with significant growth in immunotherapy combinations
- China Focus: Study conducted exclusively in China initially, leveraging HanSiZhuang’s established regulatory approval
- Competitive Positioning: Differentiates from existing EGFR inhibitors by combining with proprietary anti-PD-1 therapy
- Commercial Strategy: Potential to expand HanSiZhuang’s already-approved sqNSCLC indication with enhanced efficacy through triple combination
- Development Timeline: Phase II/III results expected 2028, with potential regulatory submission following positive outcomes
Pipeline Integration
This study represents Henlius’ strategic expansion of its oncology portfolio by:
- Maximizing value from approved HanSiZhuang platform
- Developing novel combination regimens for hard-to-treat indications
- Establishing leadership in Chinese lung cancer therapeutics
- Creating potential for international expansion following domestic success
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market expectations for HLX07 and combination therapies. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market access challenges.-Fineline Info & Tech